KZIA

Kazia Therapeutics Ltd ADR

KZIA.US kaziatherapeutics.com
11.01
-0.87 (-7.32%)
USD · NASDAQ
52-week range
4.86
17.40
Trading at 49% of the 52-week range
Market Cap
125.81M
P/E Ratio
0.00
Forward P/E
12.82
Book Value
2.95
Div. Yield
N/A
% Institutions
28.50%
% Insiders
15.42%

1 Year

+33.5%

3 Year

-79.2%

10 Year

-97.4%
Description

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Company Information

Company Name
Kazia Therapeutics Ltd ADR
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US48669G3039
CIK: 0001055886
CUSIP: 67010F103
Currency: USD
Full Time Employees: 6
Phone: 61 2 9472 4101
Fiscal Year End: June
IPO Date: Jan 06, 1999
Description:

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Address:

Three International Towers, Sydney, NSW, Australia, 2000

People

Directors & Officers

Name Title Year Born
Dr. John Edwin Friend II, M.D. Chief Executive Officer 1970
Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC Company Secretary 1973
Mr. Jeffrey Bonacorda VP of Finance & Controller NA
Mr. James E. Levine Chief Financial Officer 1971
Dr. Sudha Rao Chief Scientific Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 20, 2023 Steven Coffey N/A Purchase 27.00K $0.60 $16.20K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bleichroeder LP 400.00K Mar 31, 2026 3.50% $0.51 0.00%
Stonepine Capital Management Llc 345.18K Mar 31, 2026 3.02% $1.03 -25.02%
Point72 Asset Management, L.P. 200.00K Mar 31, 2026 1.75% $0.00 0.00%
Balyasny Asset Management LLC 193.11K Mar 31, 2026 1.69% $0.00 0.00%
F.L.Putnam Investment Management 142.47K Mar 31, 2026 1.25% $0.02 0.00%
Millennium Management LLC 101.38K Jun 30, 2026 0.89% $0.00 0.00%
Dauntless Investment Group, LLC 79.83K Mar 31, 2026 0.70% $0.39 7,983,100.00%
Westside Investment Management, Inc. 50.43K Mar 31, 2026 0.44% $0.06 63.32%
Cooperman Leon G 50.00K Jun 30, 2026 0.44% $0.02 0.00%
Royal Bank of Canada 34.34K Mar 31, 2026 0.30% $0.00 -36.56%
Barclays PLC 24.00K Mar 31, 2026 0.21% $0.00 0.00%
Sequoia Financial Advisors LLC 20.00K Jun 30, 2026 0.18% $0.00 -66.66%
UBS Group AG 13.93K Mar 31, 2026 0.12% $0.00 7,119.69%
Rockefeller Capital Management L.P. 12.70K Mar 31, 2026 0.11% $0.00 18.69%
Laird Norton Tyee Trust Co 12.40K Mar 31, 2026 0.11% $0.00 0.00%
Qube Research & Technologies 10.61K Mar 31, 2026 0.09% $0.00 0.00%
Advisor Group Holdings, Inc. 8.74K Mar 31, 2026 0.08% $0.00 87,340.00%
GAMMA Investing LLC 1.93K Jun 30, 2026 0.02% $0.00 22.83%
Rhumbline Advisers 1.40K Mar 31, 2026 0.01% $0.00 -10.42%
BNP Paribas Arbitrage, SA 1.08K Mar 31, 2026 0.01% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Exemplar Growth and Income Ser FD 163.95K 1.05% ▲ 1.55% Jul 31, 2026
2 Fidelity Nasdaq Composite Index 4.24K 0.03% ▲ 2,061.73% Jul 31, 2026
3 ActivePassive International Equity ETF 3.42K 0.02% ▲ 0.00% Aug 31, 2026

Financial Highlights

Market Cap: $125.81M
EBITDA: $-17.84M
PEG Ratio: $1.01
Book Value: $2.95
Earnings/Share: $-7.68
Profit Margin: 0.00%
Operating Margin: -14,641.04%
ROA (TTM): -25.71%
ROE (TTM): -106.90%
Revenue (TTM): $1.90M
Revenue/Share (TTM): $0.85
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 312.40%

Valuation Metrics

Enterprise Value: $134.64M
Trailing P/E: 0.00
Forward P/E: 12.82

Shares Statistics

Shares Outstanding: 11.43M
Shares Float: 9.39M
% Insiders: 15.42%
% Institutions: 28.50%
Short % Float: 4.90%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$42.00K
Gross Profit
subtotal
$42.00K
SG&A
adjust
$-8.72M
R&D
adjust
$-7.33M
Operating Income
subtotal
$-14.22M
Other / Non-Operating Items
adjust
$-6.49M
Net Income
subtotal
$-20.70M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about KZIA.US!